Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial
about
The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in ratsGlia in the cytokine-mediated onset of depression: fine tuning the immune responseAnhedonia: a concept analysisEffects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activitySKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activityPharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.Innovative solutions to novel drug development in mental healthDiscovery of novel-scaffold monoamine transporter ligands via in silico screening with the S1 pocket of the serotonin transporterPharmacological management of binge eating disorder: current and emerging treatment options.Investigational drugs for treating major depressive disorder.Beyond serotonin: newer antidepressants in the future.Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in ratsMajor depressive disorder: mechanism-based prescribing for personalized medicineRodent models of treatment-resistant depression.Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressantsMulti-modality: a new approach for the treatment of major depressive disorder.Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice.Emerging drugs for major depressive disorder.New design strategies for antidepressant drugs.Triple reuptake inhibitors: a patent review (2006 - 2012).Antidepressant drug development: Focus on triple monoamine reuptake inhibition.Impact of Antidepressant Drugs on Sexual Function and Satisfaction.The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs.Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activityEvaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study.In vitro inhibition and induction of human cytochrome P450 enzymes by SIPI5357, a potential antidepressant.Emerging drugs for major depressive disorder: an update.
P2860
Q21132285-B961EC86-5270-488C-A289-8A2F2B32E797Q26798929-BA069664-8E7B-4F42-BEC0-DA03CD8AA218Q26863341-96714F6E-EACC-4305-8548-FA786331E7BBQ28256557-12266500-D3FF-4487-A2F7-F078503C7904Q28295413-BBBE8129-539E-43D1-A440-066ADAD2FF9FQ28545209-8488BECD-D455-4C85-A00E-EBCA8ABF1EA9Q28677399-F99A5900-26F7-41A5-8831-1EBB1335FA45Q34249476-7F01505E-879C-41FA-AA1B-162D1E84DB02Q34278450-B79B9613-A40C-4D32-83D9-2601A73213B4Q34547274-587F49E1-55A5-44C6-9918-6B088AC5D984Q34557706-44203EA6-DAED-44E2-A289-9D728E763A69Q35153858-BFDAE713-35CA-4C3C-BF84-37D4EDBC7839Q35284412-A537D5E8-2565-4F61-8249-09DF75910AFEQ35580361-56E4D2A6-B345-4FEF-B3FA-7B2FC3B69A38Q36511165-4FD8F902-98C6-4AF6-9D79-E86E7FB3A23DQ36619321-4AB76D44-2EF9-41B0-885E-2008E001E694Q36896252-AAED14EC-A1AC-483C-8CAD-D799FA802B5BQ37086977-E36CA5AA-A014-47D0-B38C-9C6DF688A90FQ37158450-898E6A17-D53A-45C0-B06C-F827540E7A1CQ37700079-A31B58F9-7C8C-4EC1-B6C0-D132EF90F7ECQ37984619-E1C7F008-327B-4836-879E-48A4634B7AE5Q38132807-3E278804-0730-418C-BFC6-98AA66A168EFQ38167327-3EBA6CBA-6EE1-4A9F-BC48-5600ADE5D032Q38260259-D2F95430-4670-45A3-A160-D25284B240E0Q38620921-8FD1A355-35D6-4103-844E-B9889E3E615FQ38677673-B9379C13-32B8-4890-ABCF-18FC76DFD23FQ39780266-AB4C031A-FE7F-4FEE-B595-CC6B01279E81Q44715102-22A43608-C006-4686-8E30-FE8C05AD9837Q48095337-47621423-EC27-4038-856B-4A5BEF03D350Q48692644-533D2439-6C7E-4817-8AA6-185FE35BD9D9
P2860
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@ast
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@en
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@nl
type
label
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@ast
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@en
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@nl
prefLabel
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@ast
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@en
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@nl
P2093
P1476
Efficacy and tolerability of t ...... lind, placebo-controlled trial
@en
P2093
Anthony McKinney
Mark Bradshaw
Pal Czobor
Phil Skolnick
Pierre Tran
P356
10.1016/J.JPSYCHIRES.2011.09.003
P407
P577
2012-01-01T00:00:00Z